Browse Category

NASDAQ:APLS News 12 January 2026

Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference

Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference

New York, Jan 12, 2026, 14:41 EST — Regular session Apellis Pharmaceuticals shares dropped almost 15% Monday following the release of preliminary 2025 U.S. sales numbers ahead of its J.P. Morgan Healthcare Conference update. The move put the stock in focus as biotech firms roll out early guidance for the year. Timing is key. The J.P. Morgan meeting tends to…

Stock Market Today

  • Is AT&T Stock Still Undervalued Amid Recent Price Weakness?
    January 24, 2026, 6:00 PM EST. AT&T's (T) stock price has eased with a 4.3% decline over 30 days and a 3.9% drop year-to-date, despite an 8.4% return over the past year. Investors are considering AT&T's network investments, debt, and capital allocation when assessing value. A Discounted Cash Flow (DCF) analysis suggests AT&T is trading at a 56.5% discount to its intrinsic value of $54.25 per share, indicating possible undervaluation. The telecom giant scored 5 out of 6 in our valuation framework for being undervalued. This contrasts with short-term price softness and factors into ongoing debates about balancing income versus growth potential in the telecom sector. Investors should weigh these findings with other valuation metrics before deciding.
Go toTop